JP Morgan provided color on Medtronic MDT. In a research report published today, the rating agency commented on the criticism on the company's Infuse product.
In the report, JP Morgan states, “Last Tuesday (6/28) The Spine Journal released a scathing criticism of Medtronic's
Infuse. In an entire issue dedicated to the subject, the editors asserted (1) systematic
underreporting of adverse events in the clinical studies supporting Infuse's US
approval, (2) faulty trials designs, and (3) widespread financial conflicts of interest
among the surgeons who participated in the studies and reported the results. In the
wake of these accusations, we surveyed 48 high-volume US spine surgeons to gauge
what impact these articles might have on Infuse utilization going forward. The results
confirm that Medtronic's biologics franchise is at significant risk, with average
utilization among our respondents expected to fall by 26% over the next year.”
At the moment, JP Morgan has a Neutral rating and a price target of $41 placed on the company's stock. On Friday, Medtronic closed the week at $39.12.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in